Myeloproliferative Neoplasms Associated with Mutation in JAK۲V۶۱۷F and Tyrosine Kinase Inhibitors as Therapeutic Strategy

  • سال انتشار: 1394
  • محل انتشار: مجله تحقیق در پزشکی مولکولی، دوره: 3، شماره: 2
  • کد COI اختصاصی: JR_REMJ-3-2_001
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 85
دانلود فایل این مقاله

نویسندگان

Kaveh Tari

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Amir Atashi

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Reza Yarahmadi

Department of Laboratory Sciences, School of Paramedical Sciences, Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran

Saeid Abroun

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Abbas Hajifathali

Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Saeid Kaviani

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Masoud Soleimani

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

چکیده

MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK۲ tyrosine kinase mutation is the most common molecular lesion identified in ۹۰% of cases. JAK۲ is involved in EPO signaling pathway, and mutations in it lead to EPO-independent spontaneous phosphorylation. Most tyrosine kinase inhibitors (TKI) are small molecules that compete with ATP for binding the ATP-binding site in tyrosine kinase domains, since ATP is a source of phosphate groups used by Tks to phosphorylate the target protein.there are many TKI agent that are studing for treatment of the MPNs with JAK۲ tyrosine kinase mutation.the most important TKI drugs including CEP۷۰۱, CYT۳۸۷, LY۲۷۸۴۵۴۴, SB۱۵۱۸, TG۱۰۱۳۴۸, XL۰۱۹, INCB۱۸۴۲۴. Most important mechanism of them are reduse the splenomegaly, improvement of constitutional symptoms(improvement of bone marrow fibrosis and anemia). Although this drugs are useful but they have some side effect that common of them including Gastrointestinal disease (GI), diarrhea, nausea and vomiting, anemia, thrombocytopenia, thrombosis, leukocytosis, thrombocytosis, peripheral neuropathy, transient loss of blood pressure and lightheadedness.

کلیدواژه ها

MPN, JAK۲, TKI

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.